brexucabtagene autoleucel

AXP000015.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
Kite Pharma
Sponsor
Kite Pharma (Gilead Sciences)

Names

NameTypeSource
brexucabtagene autoleucelpreferred name, INNcurator, ncit
Tecartusbrandncit
KTE-X19codencit
brexu-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
retrovirus
Replication
non replicating
Modifications
replication-incompetent retroviral vector; murine anti-CD19 scFv linked to CD28 and CD3 zeta domains
Transgenes
anti-CD19 chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C170439
Wikidata
Q97704053
FDA UNII
4MD2J2T8SJ

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2020-07-24approvedTecartusAdults with relapsed or refractory mantle cell lymphoma, and adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiasource
EMAEU2020-12-14conditionalTecartusAdults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a BTK inhibitor; adults aged 26 and over with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiasource

Clinical trials (21)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07892027Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 22026-11-012028-05-0126Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma
NCT07763210Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 22026-09-252028-03-0159Non-hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma
NCT07673367Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 22026-07-312031-07-3125Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
NCT06553872Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLRecruitingPhase 22024-08-232029-0860Mantle Cell Lymphoma
NCT06287229Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabRecruitingPhase 1/22024-07-112028-12-3140B-cell Acute Lymphocytic Leukemia; Relapsed/Refractory
NCT06213311A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 22024-05-072027-07-3140B Cell Lymphoma
NCT06253663Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaActive not recruitingPhase 22024-03-182027-0725Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory Mantle Cell Lymphoma
NCT06482684CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingPhase 22024-02-152031-06-15150Mantle Cell Lymphoma
NCT06144606Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 22023-12-262031-07-2960Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia
NCT05993949Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaActive not recruitingPhase 12023-10-022025-07-178Lymphoblastic Leukemia
NCT05495464A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaActive not recruitingEarly phase 12022-11-182027-03-3122Lymphoma; Mantle Cell Lymphoma
NCT05537766Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedPhase 22022-11-012025-01-2719Relapsed/Refractory Burkitt Lymphoma; Relapsed/Refractory Hairy Cell Leukemia; Relapsed/Refractory Richter Transformation; Relapsed/Refractory Waldenstrom Macroglobulinemia
NCT05041309Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitation2021-12-152040-121500Autoimmune Diseases; Solid and Hematological Malignancies
NCT04880434Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)CompletedPhase 22021-04-232025-06-1795Relapsed/Refractory Mantle Cell Lymphoma
NCT03642626MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive not recruitingPhase 22018-12-182024-02-09150Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
NCT03624036Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedPhase 12018-11-152021-02-1216Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
NCT02614066A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)CompletedPhase 1/22016-03-072022-07-23125Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT02625480Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedPhase 1/22016-02-012026-03-2595Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT02601313Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedPhase 22015-11-092023-09-22105Relapsed/Refractory Mantle Cell Lymphoma
NCT05776134Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableAcute Lymphoblastic Leukemia; Mantle Cell Lymphoma
NCT04162756Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesApproved for marketingRelapse/Refractory Mantle Cell Lymphoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41052404CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.Blood advances2026name in abstract: brexucabtagene autoleucel
PMID 41160777Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.Blood2026cited by trial NCT02601313
PMID 41311365Managing Treatment-Emergent Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CAR-T Cell Therapy: A Case-Based Review of the use of Emapalumab.Hematological oncology2026name in abstract: brexucabtagene autoleucel
PMID 41487336Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy.Journal of medical cases2026name in abstract: brexucabtagene autoleucel
PMID 41568643[Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia].Recenti progressi in medicina2026name in title: brexu-cel
PMID 41568644[Case of brexu-cel at first relapse in an elderly patient].Recenti progressi in medicina2026name in title: brexu-cel
PMID 41568646[A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage].Recenti progressi in medicina2026name in title: brexu-cel
PMID 41568647[To transplant or not to transplant after CAR-T: that is the question!].Recenti progressi in medicina2026name in abstract: brexu-cel
PMID 41686452Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood advances2026cited by trial NCT02601313
PMID 41779968Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT.Blood advances2026name in title: brexu-cel
PMID 41796018Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.British journal of haematology2026name in title: brexucabtagene autoleucel
PMID 41972172Case Report: Durable remission of intraocular mantle cell lymphoma after CD19 CAR-T therapy.Frontiers in immunology2026name in abstract: brexucabtagene autoleucel
PMID 42036693Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.Journal of hematology & oncology2026cited by trial NCT02601313
PMID 42147078CAR T-cell therapy-associated central hypothyroidism: a case of a novel onco-endocrine toxicity.JCEM case reports2026name in abstract: brexucabtagene autoleucel
PMID 42178058Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.Transplantation and cellular therapy2026name in abstract: brexu-cel
PMID 42285114Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.The Lancet. Haematology2026name in abstract: brexucabtagene autoleucel
PMID 42364734Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.Transplantation and cellular therapy2026name in title: brexucabtagene autoleucel
PMID 42564502Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report.Therapeutic advances in medical oncology2026name in abstract: brexucabtagene autoleucel
PMID 42581349Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.BMC cancer2026name in abstract: brexucabtagene autoleucel
PMID 42988007Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.Transplantation and cellular therapy2026cited by trial NCT02614066
PMID 39152952Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid.Cytotherapy2025name in title: brexucabtagene autoleucel
PMID 39418622Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: brexucabtagene autoleucel
PMID 39710966Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.British journal of haematology2025name in title: brexucabtagene autoleucel
PMID 39718764Unlocking Sanctuary Sites: The Efficacy of Brexucabtagene Autoleucel in Ocular B-ALL Relapse.American journal of hematology2025name in title: brexucabtagene autoleucel
PMID 39833958Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.Journal of medical case reports2025name in abstract: brexucabtagene autoleucel
PMID 39866330Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.ACG case reports journal2025name in abstract: Tecartus
PMID 40084458[Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report].Recenti progressi in medicina2025name in abstract: brexu-cel
PMID 40084459[Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case].Recenti progressi in medicina2025name in title: brexucabtagene autoleucel
PMID 40084460[CAR-T cell therapy in a patient with relapsed/refractory mantle cell lymphoma].Recenti progressi in medicina2025name in abstract: KTE-X19
PMID 40090005Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.Blood2025name in abstract: brexucabtagene autoleucel
PMID 40203192Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.Blood advances2025name in abstract: brexucabtagene autoleucel
PMID 40209059ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.Blood2025cited by trial NCT03624036
PMID 40255392Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy.Frontiers in immunology2025name in abstract: brexucabtagene autoleucel
PMID 40334068Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.Blood advances2025name in title: brexucabtagene autoleucel
PMID 40517546First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.Hematological oncology2025cited by trial NCT06482684
PMID 40989690Posterior reversible encephalopathy syndrome after CD19 chimeric antigen receptor therapy for B-acute lymphoblastic leukemia: case report.Frontiers in oncology2025name in abstract: brexucabtagene autoleucel
PMID 41671463Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT06287229
PMID 37605437Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation.European journal of haematology2024name in abstract: brexucabtagene autoleucel
PMID 38248629Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.Leukemia & lymphoma2024name in title: brexucabtagene autoleucel
PMID 38552193Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024name in abstract: brexucabtagene autoleucel
PMID 38644613CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.European journal of haematology2024name in abstract: brexucabtagene autoleucel
PMID 38703571Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.International immunopharmacology2024name in abstract: Tecartus
PMID 39093952Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Blood advances2024name in title: brexucabtagene autoleucel
PMID 39328803Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia.Journal of medical cases2024name in title: brexucabtagene autoleucel
PMID 39474550Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.Case reports in oncology2024name in title: brexucabtagene autoleucel
PMID 35635259Use of long-term corticosteroids in patients treated with CAR T-cell therapy.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2023name in abstract: brexucabtagene autoleucel
PMID 35658525Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT02601313
PMID 36263840Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.Haematologica2023cited by trial NCT02625480
PMID 36660565Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.Radiology case reports2023name in title: brexucabtagene autoleucel
PMID 37584447The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.American journal of hematology2023name in title: brexucabtagene autoleucel
PMID 35727476Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.Advances in therapy2022cited by trial NCT02614066
PMID 35983953FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.The oncologist2022name in title: brexucabtagene autoleucel
PMID 36494725Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.Journal of hematology & oncology2022cited by trial NCT02614066
PMID 33152104Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.British journal of haematology2021name in title: brexucabtagene autoleucel
PMID 33827116KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.Blood2021cited by trial NCT02614066
PMID 34097852KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.Lancet (London, England)2021cited by trial NCT02614066
PMID 32242358KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.The New England journal of medicine2020cited by trial NCT02601313
PMID 33067318Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.Journal for immunotherapy of cancer2020cited by trial NCT02601313

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: brexucabtagene autoleucel
PMID 41026973Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.Blood advances2026name in abstract: brexucabtagene autoleucel
PMID 41207679T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.European journal of haematology2026name in abstract: brexu-cel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: brexucabtagene autoleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: brexucabtagene autoleucel
PMID 41448297Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.Critical reviews in oncology/hematology2026name in abstract: brexucabtagene autoleucel
PMID 41545665Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.Bone marrow transplantation2026name in title: brexucabtagene autoleucel
PMID 41546434Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome.Journal of neuroimaging : official journal of the American Society of Neuroimaging2026name in abstract: brexucabtagene autoleucel
PMID 41643192Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.Blood2026name in title: brexucabtagene autoleucel
PMID 41676895ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.Haematologica2026name in abstract: brexucabtagene autoleucel
PMID 41686453Brute force: the effects of ibrutinib on brexu-cel.Blood advances2026name in title: brexu-cel
PMID 41964291Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion2026name in abstract: brexu-cel
PMID 42002230Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.Transplantation and cellular therapy2026name in title: brexucabtagene autoleucel
PMID 42077190Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.American journal of hematology2026name in abstract: brexucabtagene autoleucel
PMID 42099215Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.Technology in cancer research & treatment2026name in title: Tecartus
PMID 42137294Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies.Molecular therapy. Advances2026name in title: brexucabtagene autoleucel
PMID 42242518Brexucabtagene Autoleucel in the Outpatient Setting: A Single-Institution Experience.Transplantation and cellular therapy2026name in title: brexucabtagene autoleucel
PMID 42289300Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma.British journal of haematology2026name in title: brexucabtagene autoleucel
PMID 42297689Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.Endocrinologia, diabetes y nutricion2026name in abstract: brexu-cel
PMID 42319489Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation.Annals of hematology2026name in title: brexucabtagene autoleucel
PMID 42329247Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.Oncology (Williston Park, N.Y.)2026name in abstract: brexucabtagene autoleucel
PMID 42349018Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.Blood advances2026name in title: brexucabtagene autoleucel
PMID 42449653Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.Cancers2026name in abstract: brexu-cel
PMID 42471153Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2026name in abstract: brexucabtagene autoleucel
PMID 42482164Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.Clinical pharmacology and therapeutics2026name in title: brexucabtagene autoleucel
PMID 42537846Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.Transplantation and cellular therapy2026name in title: brexucabtagene autoleucel
PMID 42753811B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: brexucabtagene autoleucel
PMID 42808549Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.Journal of managed care & specialty pharmacy2026name in title: brexucabtagene autoleucel
PMID 42844744Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review.Journal of investigative medicine : the official publication of the American Federation for Clinical Research2026name in abstract: brexucabtagene autoleucel
PMID 42844780CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.Acta clinica Belgica2026name in abstract: brexucabtagene autoleucel
PMID 42863677Impact of Prophylactic Steroids on Chimeric Antigen Receptor T-Cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.Transplantation and cellular therapy2026name in abstract: brexucabtagene autoleucel
PMID 42908664Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database.Frontiers in pharmacology2026name in abstract: Tecartus
PMID 42919964Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma.Nature medicine2026name in abstract: brexucabtagene autoleucel
PMID 42945698The summa of ZUMA: Lessons from a decade of CD19-targeted CAR-T trials in B-cell malignancies.Leukemia research2026name in abstract: brexucabtagene autoleucel
PMID 39316713The present and future of CAR T-cell therapy for adult B-cell ALL.Blood2025name in abstract: brexucabtagene autoleucel
PMID 39368017Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.PharmacoEconomics2025name in abstract: brexucabtagene autoleucel
PMID 39418599Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.Blood advances2025name in abstract: brexucabtagene autoleucel
PMID 39562721Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.Leukemia2025name in abstract: brexucabtagene autoleucel
PMID 39779930T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nature medicine2025name in abstract: brexucabtagene autoleucel
PMID 39791458Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.Leukemia & lymphoma2025name in abstract: brexucabtagene autoleucel
PMID 39913291Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.Blood cancer discovery2025name in title: brexucabtagene autoleucel
PMID 39972592Longitudinal analysis of lentiviral and retroviral chimeric antigen receptors' integration sites reveals distinct clonal evolutionary patterns.British journal of haematology2025name in abstract: brexucabtagene autoleucel
PMID 40108332Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.Leukemia2025name in title: brexucabtagene autoleucel
PMID 40127395Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.Blood advances2025name in abstract: brexucabtagene autoleucel
PMID 40146949Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network.Neurology2025name in abstract: brexu-cel
PMID 40346502Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.BMC cancer2025name in abstract: brexu-cel
PMID 40485666Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies.Therapeutic advances in drug safety2025name in abstract: brexucabtagene autoleucel
PMID 40520784Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece.Frontiers in medicine2025name in abstract: brexu-cel
PMID 40665156[CAR T cell therapy in acute lymphoblastic leukemia].Innere Medizin (Heidelberg, Germany)2025name in abstract: brexucabtagene autoleucel
PMID 40689917Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase.Therapeutic innovation & regulatory science2025name in abstract: brexucabtagene autoleucel
PMID 40706035Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.Blood advances2025name in title: brexucabtagene autoleucel
PMID 40726603Low Occurrence of Ocular Adverse Events after CAR-T Cell Therapy.Ocular oncology and pathology2025name in abstract: brexucabtagene autoleucel
PMID 40754556Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024).Discover oncology2025name in abstract: brexu-cel
PMID 40833241Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.American journal of hematology2025name in title: brexucabtagene autoleucel
PMID 40849364The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.Bone marrow transplantation2025name in title: brexucabtagene autoleucel
PMID 41090103Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.Oncoscience2025name in abstract: brexu-cel
PMID 41201546Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy.Current hematologic malignancy reports2025name in abstract: brexucabtagene autoleucel
PMID 37840282Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.Leukemia & lymphoma2024name in title: brexucabtagene autoleucel
PMID 38105391Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.European journal of haematology2024name in abstract: brexucabtagene autoleucel
PMID 38166723Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.BMC cancer2024name in abstract: brexucabtagene autoleucel
PMID 38295285Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.Blood advances2024name in abstract: brexucabtagene autoleucel
PMID 38326887The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.Experimental hematology & oncology2024name in abstract: brexucabtagene autoleucel
PMID 38350684Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.Journal for immunotherapy of cancer2024name in abstract: brexucabtagene autoleucel
PMID 38437908Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults.Critical reviews in oncology/hematology2024name in abstract: brexucabtagene autoleucel
PMID 38473919Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR).International journal of molecular sciences2024name in abstract: brexu-cel
PMID 38494076Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.Transplantation and cellular therapy2024name in title: brexucabtagene autoleucel
PMID 38494543Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.Advances in therapy2024name in title: brexucabtagene autoleucel
PMID 38498731CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.Blood advances2024name in abstract: brexucabtagene autoleucel
PMID 38544797Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.EClinicalMedicine2024name in abstract: brexu-cel
PMID 38641057Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2024name in abstract: brexucabtagene autoleucel
PMID 38667277Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.Cells2024name in abstract: brexucabtagene autoleucel
PMID 38785408Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.Leukemia & lymphoma2024name in abstract: brexucabtagene autoleucel
PMID 38817691The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?Clinical hematology international2024name in abstract: brexucabtagene autoleucel
PMID 38873532Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.HemaSphere2024name in title: brexucabtagene autoleucel
PMID 38899352Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.Haematologica2024name in title: brexucabtagene autoleucel
PMID 38926998[Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma--Review].Zhongguo shi yan xue ye xue za zhi2024name in abstract: brexucabtagene autoleucel
PMID 38975903Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.Leukemia & lymphoma2024name in abstract: brexucabtagene autoleucel
PMID 39034731FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.Current pharmaceutical biotechnology2024name in abstract: brexucabtagene autoleucel
PMID 39200107Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.Biomedicines2024name in abstract: brexu-cel
PMID 39201242A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications.International journal of molecular sciences2024name in abstract: brexu-cel
PMID 39207868Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.Blood advances2024name in title: brexucabtagene autoleucel
PMID 39234101CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023).Frontiers in pharmacology2024name in abstract: brexu-cel
PMID 39310608Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead.Cureus2024name in abstract: brexucabtagene autoleucel
PMID 39413830The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.Journal of the National Comprehensive Cancer Network : JNCCN2024name in abstract: brexucabtagene autoleucel
PMID 39559248Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.Cancer management and research2024name in title: brexucabtagene autoleucel
PMID 39632795Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review.Expert review of pharmacoeconomics & outcomes research2024name in title: brexu-cel
PMID 36585394Top advances of the year: Leukemia.Cancer2023name in abstract: brexucabtagene autoleucel
PMID 36732205Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.Blood reviews2023name in abstract: brexucabtagene autoleucel
PMID 36753699Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023name in title: brexucabtagene autoleucel
PMID 36867678CD19 CAR antigen engagement mechanisms and affinity tuning.Science immunology2023name in abstract: Tecartus
PMID 37004047CAR T-Cell therapy for the management of mantle cell lymphoma.Molecular cancer2023name in abstract: brexucabtagene autoleucel
PMID 37188352Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?British journal of haematology2023name in abstract: brexucabtagene autoleucel
PMID 37229538Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.Leukemia & lymphoma2023name in title: brexucabtagene autoleucel
PMID 37288738Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.Expert review of pharmacoeconomics & outcomes research2023name in abstract: brexucabtagene autoleucel
PMID 37339099In brief: Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukemia.The Medical letter on drugs and therapeutics2023name in title: brexucabtagene autoleucel
PMID 37518011Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.Journal of translational medicine2023name in abstract: brexucabtagene autoleucel
PMID 37536448Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.Critical reviews in oncology/hematology2023name in abstract: brexucabtagene autoleucel
PMID 37626659A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database.Biomedicines2023name in abstract: brexu-cel
PMID 37648261Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.Journal for immunotherapy of cancer2023name in title: brexucabtagene autoleucel
PMID 37654738Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma.HemaSphere2023name in title: brexucabtagene autoleucel

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA309280Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumorsCHILDREN'S HOSP OF PHILADELPHIAMA, LEYUAN2026–2026name in abstract: Tecartus
UG1HL069286BMT CTN Core- University of Pennsylvania Abramson Cancer CenterUNIVERSITY OF PENNSYLVANIASTADTMAUER, EDWARD A2024–2026name in abstract: brexu-cel
UG1HL109137Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesWASHINGTON UNIVERSITYPUSIC, ISKRA2024–2026name in abstract: brexucabtagene autoleucel

Notes

Same CAR construct as axi-cel but T-cell-enriched manufacturing; separate INN, so separate program.

How to cite

brexucabtagene autoleucel (AXP000015.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000015.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.